We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




‘Super Test’ for Prostate Cancer to Revolutionize Screening and Diagnosis

By LabMedica International staff writers
Posted on 19 Feb 2025
Print article
Image: The non-invasive ‘super test’ can detect various sub-types of prostate cancer (Photo courtesy of Adobe Stock)
Image: The non-invasive ‘super test’ can detect various sub-types of prostate cancer (Photo courtesy of Adobe Stock)

Each year, there are 55,000 new cases of prostate cancer in the UK, over 330,000 across the European Union, and more than one million men receiving treatment at any given time. Most men initially undergo prostate-specific antigen (PSA) tests as the first step in evaluating prostate cancer, but elevated PSA levels are considered unreliable for a definitive cancer diagnosis. Research has shown that approximately 70% of men with elevated PSA levels do not have cancer, while about 20% of men with normal or low PSA levels do have cancer—often an aggressive subtype that is only discovered later when there is limited time for effective treatment. To address this issue, scientists have developed a new "super test" for prostate cancer aimed at revolutionizing the screening and diagnosis of the disease, accelerating personalized treatment options for patients.

Developed by scientists at EDX Medical (Cambridge, UK), the test detects the presence or absence of cancerous cells, identifies early and late-stage cancer signs, differentiates between slow-growing and aggressive types, and assesses genetic and hereditary risks in the patient. The "super test" uses a multi-omics approach, combining proteomic, transcriptomic, genetic/hereditary, and epigenetic biomarker signatures to provide comprehensive biological data. This new test studies the most comprehensive combination of clinically validated prostate-related biomarkers known, from both blood and urine samples. It measures over 100 clinically validated biomarkers, which are then analyzed by a specially developed artificial intelligence (AI)-powered algorithm that generates a detailed report for doctors. These biomarkers have all been clinically validated and published in previous trials involving more than 31,000 positive prostate cancer samples and over 100,000 control non-cancer samples. In contrast, current advanced tests typically rely on up to 20 biomarkers per test.

In addition to biomarker data, a detailed list of phenotypic and symptom data is incorporated and analyzed simultaneously by the AI algorithm. This interpretation, driven by the proprietary AI algorithm, highlights early cancer signs and key characteristics that can inform treatment decisions. The non-invasive "super test" can identify various prostate cancer subtypes, focusing on features particularly important for patients in higher-risk non-Caucasian groups. The scientists expect the test to consistently deliver extremely high accuracy, with sensitivity and specificity between 96-99% across a broad age range and diverse ethnic groups. In comparison, current standard prostate testing, such as PSA tests and biopsies, often have accuracy rates below 50%. A highly accurate prostate cancer test would offer significant benefits for seemingly healthy men aged 45-70, as well as for healthcare providers. The improved accuracy should reduce the need for unnecessary MRI scans and significantly decrease the reliance on highly invasive digital rectal examinations (DRE).

“We have been studying this area intensively and are tremendously excited by what we believe is a truly game-changing test. Every indication thus far shows it will be the most accurate and sensitive screening test available and will be transformative in tackling prostate cancer in men who may have no idea if anything is wrong with them,” said Prof Sir Chris Evans, founder and chief scientific officer of EDX Medical. “Our integrated approach highlights the potential of combining these molecular signatures, offering a powerful, non-invasive diagnostic tool that can certainly improve clinical outcomes and help personalize treatment for patients. The incorporation of all these biomarkers into routine screening could revolutionize prostate cancer management by enabling earlier detection and more accurate risk prediction. What sets this test apart is the use of so many biomarkers with best-in-class instrument and reagent technology and our bespoke AI algorithm.”

Related Links:
EDX Medical

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
Aspergillus Test
REALQUALITY Aspergillus

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.